Absci is trading 10.49% up at $9.78 after a broad biotechnology rally on August 19, 2026.
- No new company-specific announcement was identified on August 19.
- The latest release, dated August 11, reported positive interim ABS-201 Phase 1 data and a $100 million financing, including Eli Lilly’s $40 million investment.
- Biotech strength, including Moderna’s positive cancer-vaccine trial news, is the clearest immediate catalyst.